Format

Send to

Choose Destination
Clin Cancer Res. 2014 Nov 15;20(22):5576-8. doi: 10.1158/1078-0432.CCR-14-2306. Epub 2014 Sep 16.

Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.

Author information

1
Departments of Pathology and Medicine (Section of Medical Oncology), Yale University School of Medicine and Yale Cancer Center, New Haven, Connecticut. katerina.politi@yale.edu scott.gettinger@yale.edu.
2
Medicine (Section of Medical Oncology), Yale University School of Medicine and Yale Cancer Center, New Haven, Connecticut. katerina.politi@yale.edu scott.gettinger@yale.edu.

Abstract

Mutations in ALK are a common mechanism of acquired resistance to small molecule ALK inhibitors in ALK-rearranged lung cancer. Different mutants exhibit differential sensitivity to ALK inhibitors. Matching the mutational profile of the tumor with the appropriate ALK inhibitor is likely to be important to maximize benefit for patients.

PMID:
25228532
PMCID:
PMC4401422
DOI:
10.1158/1078-0432.CCR-14-2306
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center